|
| 36165915 | Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells. | Clin Cancer Res | 2023 |
| 37628748 | APE-1/Ref-1 Inhibition Blocks Malignant Pleural Mesothelioma Cell Proliferation and Migration: Crosstalk between Oxidative Stress and Epithelial Mesenchymal Transition (EMT) in Driving Carcinogenesis and Metastasis. | Int J Mol Sci | 2023 |
| 37796435 | Cytotoxic pathways activated by multifunctional thiosemicarbazones targeting sigma-2 receptors in breast and lung carcinoma cells. | Pharmacol Rep | 2023 |
| 37902628 | 4-(3-Phenyl-4-(3,4,5-trimethoxybenzoyl)-1<i>H</i>-pyrrol-1-yl)benzenesulfonamide, a Novel Carbonic Anhydrase and Wnt/β-Catenin Signaling Pathway Dual-Targeting Inhibitor with Potent Activity against Multidrug Resistant Cancer Cells. | J Med Chem | 2023 |
| 37616241 | Fighting Multidrug Resistance with Ruthenium-Cyclopentadienyl Compounds: Unveiling the Mechanism of P-gp Inhibition. | J Med Chem | 2023 |
| 37511019 | Use of Enzymatically Activated Carbon Monoxide Donors for Sensitizing Drug-Resistant Tumor Cells. | Int J Mol Sci | 2023 |
| 37573829 | Tetrazole and oxadiazole derivatives as bioisosteres of tariquidar and elacridar: New potent P-gp modulators acting as MDR reversers. | Eur J Med Chem | 2023 |
| 37160873 | TFEB inhibition induces melanoma shut-down by blocking the cell cycle and rewiring metabolism. | Cell Death Dis | 2023 |
| 37285115 | Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 |
| 37450698 | Mitochondria Transplantation Mitigates Damage in an In Vitro Model of Renal Tubular Injury and in an Ex Vivo Model of DCD Renal Transplantation. | Ann Surg | 2023 |
| 37297007 | Long-Chain Acyl Coenzyme A Dehydrogenase, a Key Player in Metabolic Rewiring/Invasiveness in Experimental Tumors and Human Mesothelioma Cell Lines. | Cancers (Basel) | 2023 |
| 37225643 | The role of Extracellular Vesicles in glycolytic and lipid metabolic reprogramming of cancer cells: Consequences for drug resistance. | Cytokine Growth Factor Rev | 2023 |
| 36919956 | Development of Fluorescent 4-[4-(3<i>H</i>-Spiro[isobenzofuran-1,4'-piperidin]-1'-yl)butyl]indolyl Derivatives as High-Affinity Probes to Enable the Study of Ï¿ Receptors via Fluorescence-Based Techniques. | J Med Chem | 2023 |
| 36614241 | Strategies to Overcome Resistance to Immune-Based Therapies in Osteosarcoma. | Int J Mol Sci | 2023 |
| 36542836 | Development of <i>N</i>-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase. | J Med Chem | 2023 |
| 36874116 | The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines. | Front Oncol | 2023 |
| 36937872 | Editorial: Novel therapeutic approaches to target drug resistant tumors. | Front Pharmacol | 2023 |
| 36868967 | Corrigendum to 'Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein' [Pharmacol. Res. 175 (2022) 105975]. | Pharmacol Res | 2023 |
| 36674750 | mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells. | Int J Mol Sci | 2023 |
| 36657299 | N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R). | Eur J Med Chem | 2023 |
| 36927342 | A harmonized protocol for an international multicenter prospective study of nanotechnology workers: the NanoExplore cohort. | Nanotoxicology | 2023 |
| 34785319 | Glabratephrin reverses doxorubicin resistance in triple negative breast cancer by inhibiting P-glycoprotein. | Pharmacol Res | 2022 |
| 35348905 | miRNA-guided reprogramming of glucose and glutamine metabolism and its impact on cell adhesion/migration during solid tumor progression. | Cell Mol Life Sci | 2022 |
| 35545719 | TFEB controls integrin-mediated endothelial cell adhesion by the regulation of cholesterol metabolism. | Angiogenesis | 2022 |
| 35670855 | Correction to: Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. | Virchows Arch | 2022 |
| 35699521 | Electronic Coupling in 1,2,3-Triazole Bridged Ferrocenes and Its Impact on Reactive Oxygen Species Generation and Deleterious Activity in Cancer Cells. | Inorg Chem | 2022 |
| 35533249 | Splicing deregulation, microRNA and notch aberrations: fighting the three-headed dog to overcome drug resistance in malignant mesothelioma. | Expert Rev Clin Pharmacol | 2022 |
| 35461395 | Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition. | Virchows Arch | 2022 |
| 35854319 | Changes of physico-chemical properties of nano-biomaterials by digestion fluids affect the physiological properties of epithelial intestinal cells and barrier models. | Part Fibre Toxicol | 2022 |
| 35719918 | Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression. | Front Oncol | 2022 |
| 35448433 | A Biomonitoring Pilot Study in Workers from a Paints Production Plant Exposed to Pigment-Grade Titanium Dioxide (TiO<sub>2</sub>). | Toxics | 2022 |
| 35416421 | Overcoming Multidrug Resistance (MDR): Design, Biological Evaluation and Molecular Modelling Studies of 2,4-Substituted Quinazoline Derivatives. | ChemMedChem | 2022 |
| 36605214 | Immune dysfunctions affecting bone marrow Vγ9Vδ2 T cells in multiple myeloma: Role of immune checkpoints and disease status. | Front Immunol | 2022 |
| 36269278 | New Dual P-Glycoprotein (P-gp) and Human Carbonic Anhydrase XII (hCA XII) Inhibitors as Multidrug Resistance (MDR) Reversers in Cancer Cells. | J Med Chem | 2022 |
| 36171865 | Pre-validation of a reporter gene assay for oxidative stress for the rapid screening of nanobiomaterials. | Front Toxicol | 2022 |
| 35961419 | Selective delivery of pentamidine toward cancer cells by self-assembled nanoparticles. | Int J Pharm | 2022 |
| 36232858 | Naked and Decorated Nanoparticles Containing H<sub>2</sub>S-Releasing Doxorubicin: Preparation, Characterization and Assessment of Their Antitumoral Efficiency on Various Resistant Tumor Cells. | Int J Mol Sci | 2022 |
| 35953814 | Mitochondrial ROS drive resistance to chemotherapy and immune-killing in hypoxic non-small cell lung cancer. | J Exp Clin Cancer Res | 2022 |
| 35890258 | Doxorubicin-Loaded Lipid Nanoparticles Coated with Calcium Phosphate as a Potential Tool in Human and Canine Osteosarcoma Therapy. | Pharmaceutics | 2022 |
| 35880098 | Sound-based assembly of a microcapillary network in a saturn-like tumor model for drug testing. | Mater Today Bio | 2022 |
| 35321325 | A Comprehensive Evaluation of Sdox, a Promising H<sub>2</sub>S-Releasing Doxorubicin for the Treatment of Chemoresistant Tumors. | Front Pharmacol | 2022 |
| 35214025 | Targeted Self-Emulsifying Drug Delivery Systems to Restore Docetaxel Sensitivity in Resistant Tumors. | Pharmaceutics | 2022 |
| 35149209 | Sdox, a H<sub>2</sub>S releasing anthracycline, with a safer profile than doxorubicin toward vasculature. | Vascul Pharmacol | 2022 |
| 35087424 | Endothelial Cells Promote Osteogenesis by Establishing a Functional and Metabolic Coupling With Human Mesenchymal Stem Cells. | Front Physiol | 2022 |
| 35268783 | New Pharmacological Strategies against Pancreatic Adenocarcinoma: The Multifunctional Thiosemicarbazone FA4. | Molecules | 2022 |
| 35267538 | Inhibition of Heme Export and/or Heme Synthesis Potentiates Metformin Anti-Proliferative Effect on Cancer Cell Lines. | Cancers (Basel) | 2022 |
| 35197103 | SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma. | J Exp Clin Cancer Res | 2022 |
| 34864281 | Click ferrocenyl-erlotinib conjugates active against erlotinib-resistant non-small cell lung cancer cells in vitro. | Bioorg Chem | 2022 |
| 33423689 | Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons. | J Exp Clin Cancer Res | 2021 |
| 35582029 | Overcoming drug resistance in glioblastoma: new options in sight? | Cancer Drug Resist | 2021 |